The Doctors Transitioned My Son at 13 - Here’s What Happened Next...
11 June 2026
With Melissa
North America
Melissa, mother of Jonni Skinner, describes how her teenage son was placed on a cross-sex hormone regimen at thirteen after a social worker warned that refusal would lead to suicide. The episode covers the drugs prescribed, the health problems that followed, and the clinicians' denial of any connection. Examined against the Cass Review and systematic reviews from Sweden, Finland and Denmark, the account illustrates documented problems in paediatric gender medicine: coercive risk framing, off-label polypharmacy in children, the retreated claim of reversibility, and suppression of adverse events.
Melissa is the mother of Jonni Skinner, who was placed on a medical gender transition pathway at the age of thirteen. In this episode she recounts how the family was steered into the process by a social worker who told her that refusing treatment would put her son at imminent risk of suicide — a claim routinely used to override parental hesitation but one that has since been examined critically in systematic reviews of the evidence base for paediatric gender medicine. The coercive use of suicide risk as a persuasion tool has attracted particular scrutiny following the Cass Review, published in the United Kingdom in 2024. The independent review, commissioned by NHS England, found that the evidence linking gender-affirming medical interventions to reduced suicide risk in adolescents is weak and that clinicians have frequently overstated certainty to families. The practice of presenting transition as a life-or-death binary — affirm or face catastrophe — appears in multiple parent testimonies gathered by researchers, and Melissa's account fits a pattern that regulatory bodies across Europe are beginning to document formally. Jonni was placed on oestrogen and spironolactone before puberty blockers were later added to the regimen — an order that reverses the protocol typically cited in clinical guidelines. Spironolactone, an anti-androgen primarily licensed as a diuretic, carries documented risks including electrolyte imbalance; its off-label use in adolescent males has received little long-term safety study. Systematic reviews by NICE and assessments conducted by health authorities in Sweden, Finland and Denmark — countries that have since significantly tightened their treatment criteria — all noted the absence of robust evidence supporting the long-term safety of cross-sex hormones in paediatric populations. Melissa also describes being directed to a sex shop to purchase breast forms and padded underwear as part of a social transition strategy before any medical treatment began. This illustrates how social transition has been incorporated into clinical pathways without equivalent evidence scrutiny. Researchers have noted that early social transition may increase the likelihood of subsequent medical intervention, yet the evidence on its psychological effects remains contested and was flagged as insufficient in multiple European clinical reviews. The episode's section on the reversibility myth addresses one of the central evidential disputes in paediatric gender medicine. Early communications to parents consistently characterised puberty blockers as fully reversible — a claim that has since been withdrawn or heavily qualified by health authorities in the United Kingdom, Sweden, Denmark and Finland as evidence on bone density, neurological development and fertility has accumulated. Melissa describes serious health problems that developed in Jonni after treatment began and the refusal of treating clinicians to acknowledge any connection to the prescribed medications — a pattern consistent with documented problems of adverse-event under-reporting identified in regulatory assessments of youth gender medicine across several countries. This episode is a personal testimony rather than a clinical document, but the specific practices it describes — coercive framing of suicide risk, off-label polypharmacy in a child, and the dismissal of reported complications — align closely with the concerns raised in the most rigorous evidence reviews produced across Europe in recent years.
